MBMaarten O. Blanken

Maarten O. Blanken

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Maarten O. Blanken has a total of 75 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Correction to: Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

    by On Behalf Of The Dutch Rsv Neonatal Network, Maarten O. Blanken, Geert W. Frederix, Wendy J. Ungar, Elisabeth E. Nibbelke, Hendrik Koffijberg, Elisabeth A. M. Sanders, Maroeska M. Rovers, Louis Bont

    The name of the co-author Wendy J. Ungar was inadvertently omitted on the original published article. Her name and affiliation have now been added to the author list.


  • Open Access

    Risk scoring tool to predict respiratory syncytial virus hospitalisation in premature infants

    by Maarten O. Blanken, Bosco Paes, Evan J. Anderson, Marcello Lanari, Margaret Sheridan‐Pereira, Scot Buchan, John R. Fullarton, ElizaBeth Grubb, Gerard Notario, Barry S. Rodgers‐Gray, et al.

    Background: The objective was to develop a risk scoring tool which predicts respiratory syncytial virus hospitalisation (RSVH) in moderate‐late preterm infants (32‐35 weeks’ gestational age) in the Northern Hemisphere.Methods: Risk factors for RSVH were pooled from six observational studies of infants born 32 weeks and 0 days to 35 weeks and 6 days without comorbidity from 2000 to 2014. Of 13 475 infants, 484 had RSVH in the first year of life. Logistic regression was used to identify the most predictive risk factors, based on area under the receiver operating characteristic curve (AUROC). The model was validated internally by 100‐fold bootstrapping and externally with data from a seventh observational study. The model coefficients were converted into rounded multipliers, stratified into risk groups, and number needed to treat (NNT) calculated.Results: The risk factors identified in the model included (i) proximity of birth to the RSV season; (ii) second‐hand smoke exposure; and (iii) siblings and/or daycare. The AUROC was 0.773 (sensitivity: 68.9%; specificity: 73.0%). The mean AUROC from internal bootstrapping was 0.773. For external validation with data from Ireland, the AUROC was 0.707 using Irish coefficients and 0.681 using source model coefficients. Cut‐off scores for RSVH were ≤19 for low‐ (1.0%), 20‐45 for moderate‐ (3.3%), and 50‐56 (9.5%) for high‐risk infants. The high‐risk group captured 62.0% of RSVHs within 23.6% of the total population (NNT 15.3).Conclusions: This risk scoring tool has good predictive accuracy and can improve targeting for RSVH prevention in moderate‐late preterm infants.


  • Open Access

    Cost-effectiveness of rule-based immunoprophylaxis against respiratory syncytial virus infections in preterm infants

    by On Behalf Of The Dutch Rsv Neonatal Network, Maarten O. Blanken, Geert W. Frederix, Elisabeth E. Nibbelke, Hendrik Koffijberg, Elisabeth A. M. Sanders, Maroeska M. Rovers, Louis Bont

    The objective of the paper is to assess the cost-effectiveness of targeted respiratory syncytial virus (RSV) prophylaxis based on a validated prediction rule with 1-year time horizon in moderately preterm infants compared to no prophylaxis. Data on health care consumption were derived from a randomised clinical trial on wheeze reduction following RSV prophylaxis and a large birth cohort study on risk prediction of RSV hospitalisation. We calculated the incremental cost-effectiveness ratio (ICER) of targeted RSV prophylaxis vs. no prophylaxis per quality-adjusted life year (QALYs) using a societal perspective, including medical and parental costs and effects. Costs and health outcomes were modelled in a decision tree analysis with sensitivity analyses. Targeted RSV prophylaxis in infants with a first-year RSV hospitalisation risk of > 10% resulted in a QALY gain of 0.02 (0.931 vs. 0.929) per patient against additional cost of €472 compared to no prophylaxis (ICER €214,748/QALY). The ICER falls below a threshold of €80,000 per QALY when RSV prophylaxis cost would be lowered from €928 (baseline) to €406 per unit. At a unit cost of €97, RSV prophylaxis would be cost saving.Conclusions: Targeted RSV prophylaxis is not cost-effective in reducing RSV burden of disease in moderately preterm infants, but it can become cost-effective if lower priced biosimilar palivizumab or a vaccine would be available.


  • Open Access

    Interference Between Respiratory Syncytial Virus and Human Rhinovirus Infection in Infancy

    by Niek B. Achten, Pingsheng Wu, Louis Bont, Maarten O. Blanken, Tebeb Gebretsadik, James D. Chappell, Li Wang, Chang Yu, Emma K. Larkin, Kecia N. Carroll, et al.

    Respiratory syncytial virus (RSV) and human rhinovirus (HRV) are the most common viruses associated with acute respiratory tract infections in infancy. Viral interference is important in understanding respiratory viral circulation and the impact of vaccines. To study viral interference, we evaluated cases of RSV and HRV codetection by polymerase chain reaction in 2 prospective birth cohort studies (the Infant Susceptibility to Pulmonary Infections and Asthma Following RSV Exposure [INSPIRE] study and the Tennessee Children’s Respiratory Initiative [TCRI]) and a double-blinded, randomized, controlled trial (MAKI), using adjusted multivariable regression analyses. Among 3263 respiratory tract samples, 24.5% (798) and 37.3% (1216) were RSV and HRV positive, respectively. The odds of HRV infection were significantly lower in RSV-infected infants in all cohorts, with adjusted odds ratios of 0.30 (95% confidence interval [CI], .22–.40 in the INSPIRE study, 0.18 (95% CI, .11–.28) in the TCRI (adjusted for disease severity), and 0.34 (95% CI, .16–.72) in the MAKI trial. HRV infection was significantly more common among infants administered RSV immunoprophylaxis, compared with infants who did not receive immunoprophylaxis (OR, 1.65; 95% CI, 1.65–2.39). A negative association of RSV on HRV codetection was consistently observed across populations, seasons, disease severity, and geographical regions. Suppressing RSV infection by RSV immunoprophylaxis might increase the risk of having HRV infection.


  • Open Access

    Burden of Severe Respiratory Syncytial Virus Disease Among 33–35 Weeks’ Gestational Age Infants Born During Multiple Respiratory Syncytial Virus Seasons

    by Evan J. Anderson, Xavier Carbonell-Estrany, Maarten Blanken, Marcello Lanari, Margaret Sheridan-Pereira, Barry Rodgers-Gray, John Fullarton, Elisabeth Rouffiac, Pamela Vo, Gerard Notario, et al.

    BACKGROUND Moderate-late preterm infants, 33-35 weeks' gestational age (wGA), are at increased risk for respiratory syncytial virus hospitalization (RSVH). The objective of this study is to quantify the burden of RSVH in moderate-late preterm infants. METHODS A pooled analysis was conducted on RSVH from 7 prospective, observational studies in the Northern Hemisphere from 2000 to 2014. Infants' 33-35 wGA without comorbidity born during the respiratory syncytial virus season who did not receive respiratory syncytial virus immunoprophylaxis were enrolled. Data for the first confirmed RSVH during the season (+1 month) were analyzed. Incidence and hospitalization rate per 100 patient-seasons, intensive care unit admission and length of stay (LOS), oxygen support, mechanical ventilation and overall hospital LOS were assessed. RESULTS The pooled analysis comprised 7,820 infants; 267 experienced a confirmed RSVH at a median age of 8.4 weeks. The crude pooled RSVH incidence rate was 3.41% and the rate per 100 patient-seasons was 4.52. Median hospital LOS was 5.7 days. A total of 22.2% of infants required intensive care unit admission for a median LOS of 8.3 days. A total of 70.4% received supplemental oxygen support for a median of 4.9 days, and 12.7% required mechanical ventilation for a median of 4.8 days. CONCLUSIONS The burden of RSVH in moderate-late, 33-35 weeks' wGA preterm infants without comorbidities born during the viral season in Northern Hemisphere countries is substantial. Severe cases required prolonged and invasive supportive therapy.


  • Population‐Attributable Risk of Risk Factors for Recurrent Wheezing in Moderate Preterm Infants During the First Year of Life

    by Maarten O. Blanken, Koos Korsten, Niek B. Achten, Saskia Tamminga, Elisabeth E. Nibbelke, Elisabeth A.M. Sanders, Henriette A. Smit, Rolf H.H. Groenwold, Louis Bont, The Dutch Rsv Neonatal Network

    Background: Recurrent wheezing in young infants has a high prevalence, influences quality of life, and generates substantial health care costs. We previously showed that respiratory syncytial virus infection is an important mechanism of recurrent wheezing in moderate preterm infants. We aimed to provide population‐attributable risks (PAR) of risk factors for recurrent wheezing during the first year of life in otherwise healthy moderate preterm infants.Methods: RISK is a multicentre prospective birth cohort study of 4424 moderate preterm infants born at 32–35 weeks gestation. We estimated PAR of risk factors for recurrent wheezing, which was defined as three or more parent‐reported wheezing episodes during the first year of life.Results: We evaluated 3952 (89%) children at 1 year of age, of whom 705 infants (18%) developed recurrent wheezing. Fourteen variables were independently associated with recurrent wheezing. Hospitalisation for respiratory syncytial virus bronchiolitis had a strong relationship with recurrent wheezing (RR 2.6; 95% confidence interval, CI, 2.2, 3.1), but a relative modest PAR (8%; 95% CI 6, 11%) which can be explained by a low prevalence (13%). Day‐care attendance showed a strong relationship with recurrent wheezing (RR 1.9; 95% CI 1.7, 2.2) and the highest PAR (32%; 95% CI 23, 37%) due to a high prevalence (67%). The combined adjusted PAR for the 14 risk factors associated with recurrent wheezing was 49% (95% CI 46, 52%).Conclusions: In moderate preterm infants, day‐care attendance has the largest PAR for recurrent wheezing. Trial evidence is needed to determine the potential benefit of delayed day‐care attendance in this population.


  • Prediction model of RSV-hospitalization in late preterm infants: An update and validation study

    by Koos Korsten, Maarten O. Blanken, Elisabeth E. Nibbelke, Karel G.M. Moons, Louis Bont


  • Respiratory Syncytial Virus Preterm (32–36 Completed Weeks of Gestation) Risk Estimation Measure for RSV Hospitalization in Ireland

    by Margaret Sheridan-Pereira, Julie Sloan, Gloria Crispino, Anne Leahy, J. David Corcoran, Eugene Dempsey, Basil Elnazir, Patrick Gavin, Farhana Sharif, Rizwan Gul, et al.

    In several countries, respiratory syncytial virus prophylaxis is offered to late preterm infants who are at escalated risk of respiratory syncytial virus hospitalization (RSVH). However, targeted prophylaxis should be informed by country-specific data. This study, which uniquely includes 36 weeks of gestational age (GA) infants, aims to establish the risk factors for RSVH in 32-36 weeks of GA infants in Ireland. A prospective observational study at 13 hospitals of laboratory-confirmed RSVH in nonprophylaxed 32-36 weeks of GA infants was conducted from July 2011 to February 2014. Baseline and first-year clinical data were analyzed by using SPSS software Version 22 (IBM Corp, Armonk, NY). Significant (P < 0.05) variables were entered into multiple logistic regression to determine the independent risk factors for RSVH. Sixty-three percent of eligible infants (1825 of 2877) were recruited. The RSVH rate was 3.6% (65 of 1807 analyzed infant records). There was no RSV-attributable mortality. Twelve infants required intensive care. Of the 15 variables correlating to RSVH, 5 independent risk factors were identified: older siblings [odds ratio (OR): 3.8; 95% confidence interval (CI): 1.97-7.41], being Caucasian (OR: 2.3; 95% CI: 1.04-5.29), neonatal respiratory morbidity (OR: 2.2; 95% CI: 1.28-3.94); birth July 15 to December 15 (OR: 2.1; 95% CI: 1.09-3.92) and family history of asthma (OR: 1.9; 95% CI: 1.01-3.39). Birth from 36 weeks to 36 + 6 days mitigated RSVH risk (relative risk: 0.58; 95% CI: 0.34-0.99); however, risk factors were similar to the 32-35 weeks of GA cohort. Neonatal respiratory morbidity or being Caucasian were the population-specific independent risk factors for RSVH in 32-36 weeks of GA in Ireland, whereas the other identified independent risk factors mirrored those established in previous studies.


  • Cesarean Section and Hospitalization for Respiratory Syncytial Virus Infection

    by Niek B. Achten, Koos Korsten, Maarten O. Blanken, Elisabeth E. Nibbelke, Louis Bont

  • Respiratory Syncytial Virus and Recurrent Wheeze

    by Maarten O Blanken, Maroeska M Rovers, Louis Bont, Dutch Rsv Neonatal Network

    In the randomized trial reported by Blanken et al. (May 9 issue),1 the reduction of 9.7 percentage points in recurrent wheezing corresponds to a number needed to treat of 10.3. The risk of hospitalization for respiratory syncytial virus (RSV) infection and other respiratory causes was 3.7% in the palivizumab group and 7.9% in the placebo group, corresponding to a number needed to treat of 23.8. These numbers are important because of the considerable cost involved in RSV prophylaxis (approximately $6,500 per immunized child per season). Thus, the costs of preventing one hospitalization for respiratory causes in this study total more than $154,000. Although a formal cost-effectiveness analysis may follow, it would have been worthwhile to provide the numbers needed to treat and the costs of treatment.